Nucleic acid modulation of gene expression: Approaches for nucleic acid therapeutics against cancer

被引:12
|
作者
Nakata, Y [1 ]
Kim, TK [1 ]
Shetzline, S [1 ]
Gewirtz, AM [1 ]
机构
[1] Univ Penn, Sch Med, Dept Internal Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
来源
关键词
antisense oligonucleotides; RNA interference; siRNA; clinical trials; cancer therapeutics;
D O I
10.1615/CritRevEukaryotGeneExpr.v15.i2.50
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Most cancers are characterized by abnormal gene expression, which is thought to contribute to the pathogenesis and maintenance of the malignant phenotype; abnormal proliferation, maturation, and apoptosis. Silencing such genes would appear to be a rational approach to the therapy of cancer, and some preliminary clinical studies support this concept. Of the strategies available, the anti-mRNA gene silencing approach has attracted much attention and is the focus of this review. This strategy includes three types of agents: (1) single-stranded antisense ohgonudeotides; (2) catalytically active oligonucleotides, such as ribozymes, and DNAzymes that possess inherent RNA cleaving activity, and (3) small interfering RNA (siRNA) molecules that induce RNA interference (RNAi). Among these agents, antisense ohgonudeotides, especially phosphorothioate (PS) oligonucleotides, have been the most frequently used in clinical trials. In this article, we provide an overview of anti-mRNA gene silencing agents and their development for use as cancer therapeutics.
引用
收藏
页码:163 / 182
页数:20
相关论文
共 50 条
  • [1] Nucleic Acid Therapeutics
    Chaturvedi, Deo Prakash
    Ghangal, Rajesh
    Bansal, Neha
    Kumari, Sumita
    Chaithri, Kamakshi
    RESONANCE-JOURNAL OF SCIENCE EDUCATION, 2025, 30 (02): : 209 - 228
  • [2] Progress in the development of nucleic acid therapeutics for cancer
    Kalota, A
    Shetzline, SE
    Gewirtz, AM
    CANCER BIOLOGY & THERAPY, 2004, 3 (01) : 4 - 12
  • [3] DNA repair and nucleic acid therapeutics in cancer
    Sobol, Robert
    NAR CANCER, 2023, 5 (03):
  • [4] Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology
    Jepsen, JS
    Sorensen, MD
    Wengel, J
    OLIGONUCLEOTIDES, 2004, 14 (02) : 130 - 146
  • [5] Nucleic acid therapeutics - An introduction
    Gewirtz, AM
    NUCLEIC ACID THERAPEUTICS IN CANCER, 2004, : 15 - 24
  • [6] Editorial: Nucleic Acids Research and Nucleic Acid Therapeutics
    Stoddard, Barry L.
    Khvorova, Anastasia
    Corey, David R.
    Dynan, William S.
    Fox, Keith R.
    NUCLEIC ACIDS RESEARCH, 2018, 46 (04) : 1563 - 1564
  • [7] Computational approaches in design of nucleic acid-based therapeutics
    Sherman, Mark
    Contreras, Lydia
    CURRENT OPINION IN BIOTECHNOLOGY, 2018, 53 : 232 - 239
  • [8] Spherical nucleic acids: A new paradigm in nucleic acid therapeutics
    Mirkin, Chad
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [9] Nucleic Acid Therapeutics for Neurological Diseases
    Jonathan K. Watts
    Robert H. Brown
    Anastasia Khvorova
    Neurotherapeutics, 2019, 16 : 245 - 247
  • [10] Nucleic acid therapeutics in neurodevelopmental disease
    Winkelsas, Audrey M.
    Fischbeck, Kenneth H.
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 2020, 65 : 112 - 116